Haemonetics (NYSE:HAE) Releases FY 2025 Earnings Guidance

Haemonetics (NYSE:HAE) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided EPS guidance of 4.500-4.700 for the period, compared to the consensus EPS estimate of 4.590. The company issued revenue guidance of $1.3 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on HAE. Raymond James reissued a “strong-buy” rating and set a $115.00 target price (down previously from $120.00) on shares of Haemonetics in a research report on Friday. JPMorgan Chase & Co. started coverage on shares of Haemonetics in a report on Friday, December 6th. They set an “overweight” rating and a $116.00 target price on the stock. Barrington Research lowered their price target on Haemonetics from $108.00 to $95.00 and set an “outperform” rating for the company in a report on Friday. Needham & Company LLC reduced their price objective on Haemonetics from $112.00 to $108.00 and set a “buy” rating on the stock in a research note on Friday. Finally, Bank of America lowered Haemonetics from a “neutral” rating to an “underperform” rating and lowered their target price for the company from $95.00 to $68.00 in a research note on Friday. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $101.67.

Haemonetics Stock Down 4.8 %

Shares of HAE stock traded down $3.05 during mid-day trading on Friday, reaching $59.95. 1,461,955 shares of the company were exchanged, compared to its average volume of 893,223. The company has a market capitalization of $3.01 billion, a P/E ratio of 24.80, a P/E/G ratio of 1.07 and a beta of 0.39. The business’s 50 day simple moving average is $76.94 and its 200 day simple moving average is $78.62. The company has a debt-to-equity ratio of 1.39, a quick ratio of 2.09 and a current ratio of 3.49. Haemonetics has a fifty-two week low of $60.09 and a fifty-two week high of $97.97.

Haemonetics (NYSE:HAE) last issued its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.10% and a return on equity of 22.67%. Research analysts predict that Haemonetics will post 4.59 earnings per share for the current year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.